Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results